Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.59 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13509856 | 0.78 | HSD11B1 (0.58) | HSD11B1ALDH1A1 | |
| SCHEMBL16187820 | 0.75 | HSD11B1 (0.47) | HSD11B1NOTUMCYP11B2XDHIDO1 | |
| SCHEMBL18865728 | 0.75 | TSHR (0.54) | HSD11B1NOTUMCYP11B2CYP11B1XDH | |
| SCHEMBL25043902 | 0.74 | HSD11B1 (0.38) | HSD11B1ALDH1A1MAPT | |
| SCHEMBL16100377 | 0.74 | HSD11B1 (0.46) | HSD11B1NOTUMXDHIDO1TDO2 | |
| SCHEMBL20097513 | 0.73 | ALDH1A1 (0.55) | HSD11B1ALDH1A1 | |
| SCHEMBL16100223 | 0.72 | CYP11B2 (0.61) | NOTUMCYP11B2CYP11B1CYP19A1 | |
| SCHEMBL5924336 | 0.72 | KMT2A (0.61) | ALDH1A1MAPT | |
| SCHEMBL4421821 | 0.72 | PTGS2 (0.56) | HSD11B1 | |
| SCHEMBL323458 | 0.71 | NOTUM (0.51) | HSD11B1NOTUMCYP11B2CYP11B1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218194-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-07-18 | — | — | US | disclosed |
| US-20190218194-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-07-18 | — | — | US | disclosed |
| EP-3363434-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-2970131-B1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2970131-B1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170088529-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088529-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088529-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9365527-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365527-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365527-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160031839-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031839-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031839-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2970131-A2 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20140315961-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315961-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315961-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2014153100-A2 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014153100-A2 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315961-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | HSD11B1 488/4885NOTUM 572/4885CYP11B2 244/4885 |
| US-20160031839-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | HSD11B1 488/4885NOTUM 572/4885CYP11B2 244/4885 |
| US-20190218194-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | HSD11B1 488/4885NOTUM 572/4885CYP11B2 244/4885 |
| US-20170088529-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | HSD11B1 488/4885NOTUM 572/4885CYP11B2 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.